The idea of creating a gray zone in the payer message is to take the onus off of having to heavily discount for equal access ...

The growing complexity of supply chains necessitates the adoption of collaborative planning processes and capabilities such ...

The pharma tech company announced a deal with Starvision to roll out its services across the network over the next five years ...

With this is mind, Abbott announced a new program that combines one of the most popular sports in the world with education ...

The aura6000 system showed a 65% responder rate at 12 months in patients with obstructive sleep apnea, defined as achieving ...

Results from the Phase III MYR301 trial show that 36% of patients who achieved undetectable hepatitis delta virus levels when ...

Doug Long, VP, industry relations, IQVIA, discusses how soaring demand for GLP-1 therapies is driving reimbursement ...

Will Pih, co-founder, Two Labs, explains how ongoing regulatory uncertainty is slowing clinical trial activity and hiring across the industry, prompting greater reliance on specialty pharmacy services ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

Selarsdi, a biosimilar to Stelara, is approved for adult and pediatric psoriatic arthritis, plaque psoriasis, Crohn disease, ...